Cargando…
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
PURPOSE: Apixaban is often coadministered with treatments for cardiovascular comorbidities, which may lead to unintended drug–drug interactions (DDIs). The effects of apixaban on pharmacokinetics (PK) of multidose Lanoxin(®) (digoxin) and single-dose Tenormin(®) (atenolol) and the effects of single-...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327911/ https://www.ncbi.nlm.nih.gov/pubmed/28260951 http://dx.doi.org/10.2147/CPAA.S115687 |
_version_ | 1782510819469164544 |
---|---|
author | Frost, Charles Song, Yan Yu, Zhigang Wang, Jessie Lee, Lois S Schuster, Alan Pollack, Allyson LaCreta, Frank |
author_facet | Frost, Charles Song, Yan Yu, Zhigang Wang, Jessie Lee, Lois S Schuster, Alan Pollack, Allyson LaCreta, Frank |
author_sort | Frost, Charles |
collection | PubMed |
description | PURPOSE: Apixaban is often coadministered with treatments for cardiovascular comorbidities, which may lead to unintended drug–drug interactions (DDIs). The effects of apixaban on pharmacokinetics (PK) of multidose Lanoxin(®) (digoxin) and single-dose Tenormin(®) (atenolol) and the effects of single-dose atenolol on apixaban PK in healthy subjects were investigated in two Phase 1 studies. PATIENTS AND METHODS: The digoxin DDI study was an open-label, multidose, two-treatment, single-sequence study in which subjects received digoxin 0.25 mg q6h on day 1, then once daily on days 2–10, followed by apixaban 20 mg and digoxin 0.25 mg once daily on days 11–20. The atenolol DDI study was an open-label, single-dose, randomized, three-period, three-treatment, crossover study in which subjects received a single oral dose of apixaban 10 mg, atenolol 100 mg, or apixaban 10 mg plus atenolol 100 mg. The 90% confidence intervals (CIs) for the ratios of geometric means of peak plasma concentration (C(max)) and area under the concentration–time curve (AUC(tau)), with and without apixaban were calculated. Absence of effect was concluded if the point estimates and 90% CI were within the equivalence interval of 80%–125% (digoxin) or 70%–143% (atenolol). A similar analysis was performed to assess the effect of atenolol on apixaban. RESULTS: Apixaban had no clinically relevant effect on the PK of either atenolol or digoxin: point estimates and 90% CI for both digoxin and atenolol C(max) and AUC were entirely within their respective no-effect intervals. Apixaban C(max) and AUC(inf) were slightly decreased (ie, 18% and 15% lower, respectively) following atenolol coadministration. No serious or major bleeding-related adverse events were reported during either study. CONCLUSION: Apixaban had no effect on the PK of digoxin and there was no clinically relevant interaction between apixaban and atenolol. Coadministration of digoxin or atenolol with apixaban in healthy subjects was generally well tolerated. |
format | Online Article Text |
id | pubmed-5327911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53279112017-03-03 The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects Frost, Charles Song, Yan Yu, Zhigang Wang, Jessie Lee, Lois S Schuster, Alan Pollack, Allyson LaCreta, Frank Clin Pharmacol Original Research PURPOSE: Apixaban is often coadministered with treatments for cardiovascular comorbidities, which may lead to unintended drug–drug interactions (DDIs). The effects of apixaban on pharmacokinetics (PK) of multidose Lanoxin(®) (digoxin) and single-dose Tenormin(®) (atenolol) and the effects of single-dose atenolol on apixaban PK in healthy subjects were investigated in two Phase 1 studies. PATIENTS AND METHODS: The digoxin DDI study was an open-label, multidose, two-treatment, single-sequence study in which subjects received digoxin 0.25 mg q6h on day 1, then once daily on days 2–10, followed by apixaban 20 mg and digoxin 0.25 mg once daily on days 11–20. The atenolol DDI study was an open-label, single-dose, randomized, three-period, three-treatment, crossover study in which subjects received a single oral dose of apixaban 10 mg, atenolol 100 mg, or apixaban 10 mg plus atenolol 100 mg. The 90% confidence intervals (CIs) for the ratios of geometric means of peak plasma concentration (C(max)) and area under the concentration–time curve (AUC(tau)), with and without apixaban were calculated. Absence of effect was concluded if the point estimates and 90% CI were within the equivalence interval of 80%–125% (digoxin) or 70%–143% (atenolol). A similar analysis was performed to assess the effect of atenolol on apixaban. RESULTS: Apixaban had no clinically relevant effect on the PK of either atenolol or digoxin: point estimates and 90% CI for both digoxin and atenolol C(max) and AUC were entirely within their respective no-effect intervals. Apixaban C(max) and AUC(inf) were slightly decreased (ie, 18% and 15% lower, respectively) following atenolol coadministration. No serious or major bleeding-related adverse events were reported during either study. CONCLUSION: Apixaban had no effect on the PK of digoxin and there was no clinically relevant interaction between apixaban and atenolol. Coadministration of digoxin or atenolol with apixaban in healthy subjects was generally well tolerated. Dove Medical Press 2017-02-23 /pmc/articles/PMC5327911/ /pubmed/28260951 http://dx.doi.org/10.2147/CPAA.S115687 Text en © 2017 Frost et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Frost, Charles Song, Yan Yu, Zhigang Wang, Jessie Lee, Lois S Schuster, Alan Pollack, Allyson LaCreta, Frank The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
title | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
title_full | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
title_fullStr | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
title_full_unstemmed | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
title_short | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
title_sort | effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327911/ https://www.ncbi.nlm.nih.gov/pubmed/28260951 http://dx.doi.org/10.2147/CPAA.S115687 |
work_keys_str_mv | AT frostcharles theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT songyan theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT yuzhigang theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT wangjessie theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT leeloiss theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT schusteralan theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT pollackallyson theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT lacretafrank theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT frostcharles effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT songyan effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT yuzhigang effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT wangjessie effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT leeloiss effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT schusteralan effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT pollackallyson effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT lacretafrank effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects |